Proloprim

Shigellosis, Nocardiosis, Brucellosis + 16 more

Treatment

17 FDA approvals

17 Active Studies for Proloprim

What is Proloprim

Trimethoprim

The Generic name of this drug

Treatment Summary

Trimethoprim is an antibiotic that works by blocking a bacterial enzyme called dihydrofolate reductase. By blocking this enzyme, Trimethoprim prevents the growth of bacteria in the body. It is often used in combination with another antibiotic called sulfamethoxazole, but it can also be used on its own to treat urinary tract infections. Trimethoprim is related to another drug called pyrimethamine, which is used to treat parasitic infections.

Septra DS

is the brand name

image of different drug pills on a surface

Proloprim Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Septra DS

Trimethoprim

1973

343

Approved as Treatment by the FDA

Trimethoprim, also called Septra DS, is approved by the FDA for 17 uses including susceptible Enteritis infectious caused by Shigella sonnei and Cholera .

susceptible Enteritis infectious caused by Shigella sonnei

Used to treat susceptible Enteritis infectious caused by Shigella sonnei in combination with Sulfamethoxazole

Cholera

Used to treat susceptible Cholera in combination with Sulfamethoxazole

Urinary tract infection

Used to treat Urinary Tract Infection caused by susceptible bacteria in combination with Sulfamethoxazole

Nocardiosis

Used to treat Nocardiosis in combination with Sulfamethoxazole

Fluid replacement therapy

Used to treat Fluid replacement therapy in combination with Sulfamethoxazole

Pneumonia, Pneumocystis

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Genus Pneumocystis

Used to treat risk of Pneumocystis jiroveci pneumonia (PCP) in combination with Sulfamethoxazole

Otitis Media

Used to treat Acute Otitis Media caused by susceptible bacteria in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Electrolyte replacement

Used to treat Electrolyte replacement in combination with Sulfamethoxazole

Pneumocystis Jirovecii Pneumonia

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Shigellosis

Used to treat Dysentery, Bacillary in combination with Sulfamethoxazole

Bronchitis

Used to treat Acute Exacerbation of Chronic Bronchitis (AECB) caused by susceptible bacteria in combination with Sulfamethoxazole

Diarrhea

Used to treat susceptible Travelers' Diarrhea caused by Enterotoxigenic E. Coli (ETEC) Infection in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella flexneri

Used to treat susceptible Enteritis infectious caused by Shigella flexneri in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Immunocompromised

Used to treat Immunocompromised in combination with Sulfamethoxazole

Effectiveness

How Proloprim Affects Patients

Trimethoprim works by disrupting the process bacteria use to make proteins and make their DNA. It is effective against several types of bacteria, but can develop resistance. In rare cases, it can cause blood disorders like low platelet or white blood cell counts, as well as sore throat, fever, pale skin, and purple spots on the skin. It's important to check with your local area to see what kinds of bacteria this drug is effective against.

How Proloprim works in the body

Trimethoprim stops bacteria from making a chemical, tetrahydrofolic acid, that they need to survive. It works by blocking an enzyme in the bacteria that helps create this chemical. When given with another drug, sulfamethoxazole, it can stop two steps in the production of the chemical, which can be enough to kill the bacteria. On its own, trimethoprim just slows the bacteria's growth, but together with sulfamethoxazole, it can be a powerful weapon against bacterial infections.

When to interrupt dosage

The proposed measure of Proloprim is contingent upon the diagnosed condition, including Urinary tract infection, Immunocompromised and Pneumocystis Jirovecii Pneumonia. The quantity of dosage is contingent upon the technique of dispensation (e.g. Tablet - Oral or Tablet) noted in the table beneath.

Condition

Dosage

Administration

Pneumonia, Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Conjunctivitis, Bacterial

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Brucellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Immunocompromised

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Nocardiosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

bacterial blepharitis caused by susceptible bacteria

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Diarrhea

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Shigellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Electrolyte replacement

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Fluid replacement therapy

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Genus Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Bacterial conjunctivitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Bronchitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

susceptible Enteritis infectious caused by Shigella flexneri

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

susceptible Enteritis infectious caused by Shigella sonnei

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Otitis Media

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Cholera

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic, Liquid

Warnings

Proloprim has eight recognized contraindications and should not be combined with the conditions given in the below table.

Proloprim Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

Purpura, Thrombocytopenic, Idiopathic

Do Not Combine

hepatic damage

Do Not Combine

Megaloblastic anemia caused by Folate deficiency

Do Not Combine

unable to monitor renal function

Do Not Combine

Disease

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

There are 20 known major drug interactions with Proloprim.

Common Proloprim Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Trimethoprim.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Trimethoprim.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Trimethoprim.

Cisplatin

Major

The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim.

Clofarabine

Major

The serum concentration of Clofarabine can be increased when it is combined with Trimethoprim.

Proloprim Toxicity & Overdose Risk

The lowest toxic dose of trimethoprim in mice and rats is 2764 mg/kg and greater than 5300 mg/kg respectively. Taking more than 1 gram of trimethoprim may lead to signs of overdose such as nausea, vomiting, dizziness, headaches, confusion, and reduced bone marrow activity. Treatment should involve supportive care and possibly stomach pumping. Acidifying the urine may help to remove the drug from the body. Hemodialysis may be somewhat effective, but peritoneal dialysis will not help.

image of a doctor in a lab doing drug, clinical research

Proloprim Novel Uses: Which Conditions Have a Clinical Trial Featuring Proloprim?

8 active clinical trials are currently being conducted to explore the potential of Proloprim to treat susceptible Enteritis infectious caused by Shigella flexneri, Blepharoconjunctivitis caused by susceptible bacteria and Diarrhea.

Condition

Clinical Trials

Trial Phases

Urinary tract infection

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Bronchitis

0 Actively Recruiting

Nocardiosis

0 Actively Recruiting

Shigellosis

0 Actively Recruiting

Brucellosis

0 Actively Recruiting

bacterial blepharitis caused by susceptible bacteria

0 Actively Recruiting

Immunocompromised

3 Actively Recruiting

Not Applicable, Phase 1

Otitis Media

0 Actively Recruiting

Genus Pneumocystis

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

Fluid replacement therapy

0 Actively Recruiting

Cholera

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

susceptible Enteritis infectious caused by Shigella sonnei

0 Actively Recruiting

Pneumonia, Pneumocystis

1 Actively Recruiting

Phase 3

susceptible Enteritis infectious caused by Shigella flexneri

0 Actively Recruiting

Electrolyte replacement

0 Actively Recruiting

Diarrhea

14 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Early Phase 1

Proloprim Reviews: What are patients saying about Proloprim?

4.7

Patient Review

3/17/2011

Proloprim for Urinary Tract Infection

2.3

Patient Review

8/3/2013

Proloprim for Urinary Tract Infection

Unfortunately, this medication made me feel almost as bad as the bladder infection itself. I will be requesting a different option from my doctor if I ever experience cystitis again.

2.3

Patient Review

6/27/2014

Proloprim for Bacterial Urinary Tract Infection

This medication raised my potassium levels to a dangerously high level.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about proloprim

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of taking trimethoprim?

"These may be symptoms of a serious condition called sepsis."

Answered by AI

What is DermacinRx used for?

"Diclofenac is an anti-inflammatory drug that is not a steroid. It is a combination medicine that is used to treat joint pain, stiffness, and swelling caused by osteoarthritis of the knees."

Answered by AI

What is Proloprim used for?

"It Jun 3, 2022 is used to treat bacterial infections."

Answered by AI

What is the mechanism of action of trimethoprim?

"Trimethoprim prevents the reduction of dihydrofolate to tetrahydrofolate, which is the active form of folic acid. It is effective against most gram-positive aerobic cocci and some gram-negative aerobic bacilli."

Answered by AI

Clinical Trials for Proloprim

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Proloprim clinical trials?

We made a collection of clinical trials featuring Proloprim, we think they might fit your search criteria.
Go to Trials

Have you considered Proloprim clinical trials?

We made a collection of clinical trials featuring Proloprim, we think they might fit your search criteria.
Go to Trials
Image of McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) in Montreal, Canada.

Low-Dose Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia

18 - 100
All Sexes
Montreal, Canada

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX. Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.

Phase 3
Waitlist Available

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

Emily G McDonald, MD MSc

Image of Temple University in Philadelphia, United States.

UV Water Treatment for Gastroenteritis in Children

6 - 59
All Sexes
Philadelphia, PA

Approximately 40 million people in the US are served by private, and frequently untreated, wells. Our best estimate is that 1.3 million cases of gastrointestinal illnesses (GI) per year are attributed to consuming water from untreated private wells in the US, but in reality, there are no robust epidemiological data that can be used to estimate cases of GI attributable to these sources. We propose the first randomized controlled trial (RCT) to estimate the burden of GI associated with private well water. We will test if household treatment of private well water by ultraviolet light (UV) vs. sham (inactive UV device) decreases the incidence of GI in children under 5. We will also examine the presence of viral, bacterial, and protozoan pathogens in stool and well water from participants. These data will fill a knowledge gap on sporadic GI associated with federally-unregulated private water supplies in the US.

Recruiting
Paid Trial

Temple University

Heather M Murphy, PhD

Have you considered Proloprim clinical trials?

We made a collection of clinical trials featuring Proloprim, we think they might fit your search criteria.
Go to Trials